Lenalidomide Glenmark

Lenalidomide, the active ingredient in Lenalidomide Glenmark, is an Immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It treats multiple myeloma and myelodysplastic syndromes in adult patients.

GNH USA supplies Lenalidomide Glenmark as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is used in hematologic malignancies and related bone‑marrow disorders, targeting abnormal plasma‑cell and stem‑cell proliferation.

Multiple Myeloma: improves progression‑free and overall survival in patients receiving combination therapy. Myelodysplastic Syndromes: reduces transfusion dependence and improves blood counts. MDS with del(5q): induces cytogenetic remission and decreases need for supportive care.

Lenalidomide may cause a range of adverse reactions, from mild to severe. Monitoring and supportive care are essential during therapy.

Common Side Effects: - Neutropenia: reduced white‑blood‑cell count. - Thrombocytopenia: lowered platelet levels. - Fatigue: persistent tiredness. - Diarrhea: loose stools. - Rash: skin irritation or erythema. - Constipation: difficulty passing stool.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein clot or pulmonary embolism. - Severe neutropenia: heightened infection risk. - Severe thrombocytopenia: increased bleeding tendency. - Tumor lysis syndrome: rapid tumor cell breakdown. - Secondary malignancies: emergence of new cancers. - Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome.

Before initiating Lenalidomide, clinicians should assess patient‑specific risk factors and implement appropriate monitoring.

Pregnancy: contraindicated; teratogenic risk requires strict pregnancy prevention. Blood counts: monitor complete blood count regularly for cytopenias. Thromboembolic risk: assess need for prophylactic anticoagulation. Renal impairment: adjust dose in patients with reduced kidney function. Hepatic impairment: consider dose modification for liver disease. Store at ambient temperature: keep in original container, protect from moisture and light.

Lenalidomide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Thalidomide or other IMiDs: additive teratogenic and hematologic toxicity. - Strong CYP inducers (e.g., rifampin): may reduce drug exposure.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened renal toxicity. - Live vaccines: reduced immunogenicity, avoid during therapy. - Certain antibiotics (e.g., erythromycin): may affect blood‑count recovery. - Hormonal contraceptives: decreased effectiveness, use additional barrier methods.